Grocery business Publix said on Tuesday that its is suspending the administration of the Johnson & Johnson COVID-19 vaccine at all of its pharmacy locations following guidance from the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA).
The CDC and FDA have issued a joint media statement with additional information about the Johnson & Johnson COVID-19 vaccine.
While a rare side effect, individuals who have received the Johnson & Johnson COVID-19 vaccine should contact their health care provider if they develop a severe headache, abdominal pain, leg pain or shortness of breath within three weeks, according to the CDC and FDA.
However, the customers can visit publix.com/covidvaccine to schedule an appointment for the Moderna COVID-19 vaccine, if currently available in their state.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT